In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

PreSCD II: Prevention of Sudden Cardiac Death in Post Myocardial Infarction Patients: Risk Stratification, ICD Therapy Penetration and Related Longterm Outcome - Final Results of the German PreSCD II Registry

Hot Line III

Sudden Cardiac Death and Resuscitation



Presenter | see Discussant report

Voeller, HeinzVoeller, Heinz, FESC (Germany)

 

 

 

 

 

Presentation webcast

Presentation slides

List of Authors:

H. Völler, W. Kamke, H. U. Klein, M. Block, R. Reibis, S. Treusch, K. Contzen, K. Wegscheider

Abstract:


Current guidelines recommend implantable cardioverter-defibrillator (ICD) therapy for primary prevention of sudden cardiac death (SCD) in patients with reduced left ventricular function (LVEF = 30-35%) more than 40 days after myocardial infarction (MI). The aim of the prospective Prevention of Sudden Cardiac Death II (PreSCD II) registry was to investigate daily practice of ICD therapy in post-MI patients and to evaluate their long-term survival. Methods: 10,612 consecutive post MI patients (61±12 years, 76% male) were enrolled in 19 cardiac rehabilitation (CR) centers in Germany from December 2002 to May 2005. All patients with LVEF = 40% together with a random subsample with preserved left ventricular function (LVEF > 40%) were followed for 36 months. Logistic regression modeling was applied to characterize patients with ICD therapy. Cox proportional hazard models with ICD therapy as time-dependent covariate were used to study overall survival. Results: 77.4% of all patients were enrolled within 60 days, 10.7% more than one year after MI. 269 patients (2.5%, Group 1) had LVEF = 30% and 727 patients (6.9%, Group 2) had LVEF 31-40%. Follow-up was performed in a total of 2,058 patients, 259 in Group 1, 693 in Group 2 and 1,106 in Group 3 (LVEF > 40%). Seventy-five patients received an ICD within four months after risk stratification, 57 (22%) in Group 1 and 15 (2.2%) in Group 2. After 36 months 142 (6.9%) patients had received an ICD, 47% of them within one year after their index MI. ICD implantation was mainly driven by LVEF = 30% and to a lesser extent by non-sustained ventricular tachycardia, prior syncope, NYHA II-IV, prolonged QRS, renal insufficiency, and more remote index MI. ICD patients had an adjusted 44% lower mortality (HR 0. 56, 95% CI 0.32-1.01; p=0.053) than comparable patients without ICD therapy. There was a significant trend towards lower mortality of ICD recipients if the device was implanted in the remote phase of MI (p<0.001).

Conclusions: The PreSCD II registry showed a low prevalence of patients with reduced left ventricular function after MI. Few patients with guideline-based ICD indication received ICD therapy. Mortality was reduced if an ICD was implanted late after MI.

 

 


Discussant | see Presenter abstract

Vardas, Panagiotis FESC (Greece)

Presentation webcast

Presentation slides

Report:

Access the slides from the discussant

References


3590-3591

SessionTitle:

Prevention of Sudden Cardiac Death in Post Myocardial Infarction Patients: Risk Stratification, ICD Therapy Penetration and Related Longterm Outcome: Final Results of the German PreSCD II Registry

Notes to editor


This congress report accompanies a presentation given at the ESC Congress 2009. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.